Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

Edward Kim  |

We've been following Vericel (Nasdaq: VCEL), a specialty biologics company with three approved cellular therapy products on the market, and we wonder whether or not the company may still be underappreciated by investors after its recent run. Vericel's second quarter numbers, reported earlier this month, showed strong growth in revenues and gross margin year-over-year, driven by sales of its newly introduced MACI implant for the treatment of symptomatic cartilage defects in the knee.

The company's three commercial products are the result of its research and development in autologous cell therapy, in which a patient’s own cells are used to treat a condition or disease. The cells are collected from the patient and then expanded or multiplied outside the body, before being reintroduced to the same patient for therapeutic benefit. The patient effectively acts as his or her own donor. Advantages for this type of cell therapy include minimizing the risk of rejection and therefore the need for potentially toxic immunosuppressive therapy.

Commercial Product Line

MACI (autologous cultured chondrocytes on porcine collagen membrane) was approved by the FDA in December 2016 as an implantable scaffold to repair symptomatic, full-thickness cartilage defects of the knee in adults. (Chondrocytes are cartilage cells.) MACI is the first FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee.

Carticel is used to repair articular cartilage injuries in the knee in patients who've had inadequate responses to prior arthroscopic or other surgical procedures. Carticel consists of a patient’s own harvested chondrocytes which are then multiplied into millions of cells before being implanted into the knee cartilage defect and generating repair tissue.

Epicel is a skin graft grown from a patient’s own skin, providing replacement for deep dermal or full thickness burns comprising a total body surface area of at least 30%. From two postage stamp-sized biopsies, Vericel can grow enough skin to cover the patient’s entire body. Epicel may be used in conjunction with split-thickness autografts (including the epidermis and part of the dermis) or alone in patients for whom split-thickness autografts may not be an option due to the severity and extent of their burns.

In development: Ixmyelocel-T for Advanced Heart Failure

The company's ixmyelocel-T candidate, a multicellular therapy produced from a patient's own bone marrow, for treating patients with advanced heart failure due to ischemic dilated cardiomyopathy received Fast Track designation from the FDA in February 2017. Vericel's Phase 2b data showed last year that ixmyelocel-T met the primary endpoint of a reduction in the total number of all-cause deaths, cardiovascular hospitalizations or unplanned outpatient and emergency department visits to treat acute decompensated heart failure during the 12 months following treatment compared to placebo.

Subsequently, in May 2017, Vericel received the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for ixmyelocel-T, becoming the first company to receive the RMAT designation for the treatment of a serious cardiovascular disease.

Q2 Highlights

VCEL Stock

Vericel has had a pronounced summer rally, with shares up over 75% from their mid-June lows. With a current market value of just $150 million, however, the stock still feel undervalued given the addressable market sizes for the product line in the US alone.

COVID-19: Consumer Brands Association Presses White House for More Clarity on Vaccine Mandates

One issue that the company will need to address is maintaining its operating capital. There was $14 million in cash on the balance sheet as of June 30th, with a term loan and revolver outstanding of $10.5 million. Vericel raised $20 million in a December 2016 follow-on and $6 million in a licensing agreement in May 2017. The company used $8.8 million in cash for operating activities in the first half of 2017.

We like the risk-reward at this level and are encouraged by the growth in revenues and margins. We'll be watching for continued signs of growth this quarter from the product line and further developments related to ixmyelocel-T for advanced heart failure.

Please email us at content@equities.com to see our Case Studies and Testimonials.

Please click here for information on our new trading platform.

Please click here to subscribe to our complimentary newsletter.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Market Movers

Sponsored Financial Content